TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19035530

Group type: EXPERIMENTAL
Intervention: Natural direct effect bounds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled direct effect bounds
Number of subjects: 0
Study: 17035445

Group type: EXPERIMENTAL
Intervention: Intranasal trivalent, live attenuated, cold‐adapted influenza virus vaccine (TC)
Number of subjects: 2215

Group type: COMPARATOR
Intervention: Intranasal placebo (TP)
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: Laboratory‐documented influenza (LDI)‐caused illness
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: Acute respiratory illness
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: No illness
Number of subjects: 2215
Study: 15167171

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Enoxaparin or unfractionated heparin (control)
Number of subjects: 1639
Study: 11225418

Group type: EXPERIMENTAL
Intervention: 125 mA or 150 mA tube current in group A (weight < 60 kg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 150, 175 or 200 mA tube current in group B (weight 60-80 kg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 150 mA tube current in group C (weight > 80 kg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Body weight adjusted tube current
Number of subjects: 77
Study: 9430084

Group type: EXPERIMENTAL
Intervention: A16 soybean oil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Commercial soybean oil
Number of subjects: 15

Group type: COMPARATOR
Intervention: Coconut oil
Number of subjects: 15
Study: 8213578

Group type: EXPERIMENTAL
Intervention: Enalapril (1 mg infusion followed by oral treatment to a target dose of 20 mg/day)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 428
Study: 3315271

Group type: EXPERIMENTAL
Intervention: BID (twice-daily, equally divided 12 hr)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: OD-PM (once-daily evening)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: OD-AM (once-daily morning)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study: 29958328

Group type: EXPERIMENTAL
Intervention: Adequately physically active
Number of subjects: 5611

Group type: EXPERIMENTAL
Intervention: Inadequately physically active
Number of subjects: 5611

Group type: COMPARATOR
Intervention: Inactive
Number of subjects: 5611
Study: 27687373

Group type: EXPERIMENTAL
Intervention: Deep NMB (posttetanic count, < 5)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Moderate NMB (train‐of‐four count, 1‐3)
Number of subjects: 76
Study: 25175480

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination inhaler (SFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No FP dose change
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increased FP dose
Number of subjects: 0
Study: 22759324

Group type: COMPARATOR
Intervention: ST + placebo
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: ST + LF + PB
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: ST + PB
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: All groups (ST + placebo, ST + LF + PB, ST + PB)
Number of subjects: 227
Study: 20083352

Group type: EXPERIMENTAL
Intervention: Lidocaine injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical clonazepam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HAD score
Number of subjects: 20
Study: 18724209

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no ITB treatment)
Number of subjects: 100
Study: 15910297

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) administered at a daily oral dose of 2 x 1000 mg for the first 6 postoperative months, tapered within 2 weeks thereafter.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group received fluocortolon and topical prednisolone acetate, no specific intervention mentioned.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) group.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups experienced side effects, particularly gastroenterotoxicity, tachycardia, arthralgia, or systemic infections.
Number of subjects: 86
Study: 11156812

Group type: EXPERIMENTAL
Intervention: Bupropion (up to 200 mg b.i.d.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9625292

Group type: EXPERIMENTAL
Intervention: Insulin plus nicotinamide (0.5 g, three tablets/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Current sulphonylureas plus nicotinamide (0.5 g, three tablets/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Insulin plus placebo (3 tablets/day)
Number of subjects: 18
Study: 7836197

Group type: EXPERIMENTAL
Intervention: Aminophylline (5 mg/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Dipyridamole (0.6 mg/kg)
Number of subjects: 9
Study: 3282078

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2B therapy for an additional 6 months (18 months total)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No further therapy after 12 months of interferon alfa-2B
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Re-treatment with interferon alfa-2B after relapse
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2B therapy (standard dose of 2 X 10(6) U/m2 sc three times weekly)
Number of subjects: 90
Study: 31482404

Group type: EXPERIMENTAL
Intervention: Orange color room
Number of subjects: 0

Group type: COMPARATOR
Intervention: White color room
Number of subjects: 0
Study: 29409133

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg (anti-TNF-naive)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg (anti-TNF-naive)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo (anti-TNF-naive)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg (anti-TNF-IR)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg (anti-TNF-IR)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo (anti-TNF-IR)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg and 150 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: MDA responders
Number of subjects: 292
Study: 28013272

Group type: EXPERIMENTAL
Intervention: CSC-T (8-session, group-based comprehensive smoking cessation and trauma management treatment)
Number of subjects: 90

Group type: COMPARATOR
Intervention: CSC (comprehensive smoking cessation alone)
Number of subjects: 90
Study: 23542112

Group type: EXPERIMENTAL
Intervention: Adult CHD patients with a >3-year gap in cardiology care
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Adult CHD patients with mild, moderate, and severe disease
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Clinic location
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Common reasons for gaps in care
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Reasons for returning to care
Number of subjects: 922
Study: 21612744

Group type: EXPERIMENTAL
Intervention: Amikacin 125 ‐ 1,000 mg once‐daily or every‐other‐day
Number of subjects: 305
Study: 20115931

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 322

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 322
Study: 17183433

Group type: EXPERIMENTAL
Intervention: Direct transfer to PCI centre from on-site (group 1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Transfer after initial treatment in local emergency room (group 2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Transfer after initial treatment in local emergency room (group 3)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Overall rate of Major Adverse Cardiac Events (MACE)
Number of subjects: 42
Study: 15271158

Group type: EXPERIMENTAL
Intervention: Intravenous fluid warmer set at 38.5 degrees C on the dialysate and 1 L/hour of replacement fluid lines
Number of subjects: 60

Group type: COMPARATOR
Intervention: No fluid warmer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (with and without fluid warmer)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lower baseline temperature
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 60
Study: 11785857

Group type: EXPERIMENTAL
Intervention: Vignette patients with risk factors for preterm birth
Number of subjects: 301

Group type: COMPARATOR
Intervention: Vignette patients without risk factors for preterm birth
Number of subjects: 301
Study: 9377662

Group type: EXPERIMENTAL
Intervention: Prostatic carcinoma (PC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Benign prostatic hyperplasia (BPH)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 38
Study: 7898095

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic antihypertensive therapy
Number of subjects: 0
Study: 3390235

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Counselling by a trained assistant nurse and a physician
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control Group (CG) - No specific intervention mentioned
Number of subjects: 120
Study: 31556524

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 50
Study: 28394459

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg BID)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (719 mg maltodextrin)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 13
Study: 26392152

Group type: EXPERIMENTAL
Intervention: High-fat, high-AGE (HFHA) diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-fat, high-AGE (LFHA) diet
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 19
Study: 24138400

Group type: EXPERIMENTAL
Intervention: VR training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 21700360

Group type: EXPERIMENTAL
Intervention: 5% minoxidil topical foam (MTF) once daily
Number of subjects: 113

Group type: COMPARATOR
Intervention: 2% minoxidil topical solution (MTS) twice daily
Number of subjects: 113
Study: 17901091

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study: 22146488

Group type: EXPERIMENTAL
Intervention: Active breathing training program
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 15644834

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 12590213

Group type: EXPERIMENTAL
Intervention: rhBMP-2 on an absorbable collagen sponge
Number of subjects: 42

Group type: COMPARATOR
Intervention: Autogenous iliac crest bone graft
Number of subjects: 42
Study: 9607117

Group type: EXPERIMENTAL
Intervention: Usual alcohol intake
Number of subjects: 55

Group type: COMPARATOR
Intervention: Low alcohol beer
Number of subjects: 55
Study: 7638994

Group type: EXPERIMENTAL
Intervention: Intrathoracic local anesthetics via intrapleural catheter (IPCs)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Systemic narcotic medications
Number of subjects: 42
Study: 2507224

Group type: EXPERIMENTAL
Intervention: Enteral feeding via needle catheter jejunostomy (NCJ) starting 12 hours postoperatively, advanced to 100-125 ml/h of full-strength diet
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no enteral nutrition during the first 5 days)
Number of subjects: 123
Study: 782777

Group type: EXPERIMENTAL
Intervention: Amine fluoride daily
Number of subjects: 468

Group type: COMPARATOR
Intervention: Acidulated phosphate fluoride daily
Number of subjects: 468

Group type: COMPARATOR
Intervention: Amine fluoride weekly
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo weekly
Number of subjects: 468
Study: 31780025

Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27847235

Group type: EXPERIMENTAL
Intervention: FBR1 (HRT of 8h) with ethanol and nitrate addition (Phase II)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: FBR1 (HRT of 8h) with nitrate (Phase IV)
Number of subjects: 2

Group type: COMPARATOR
Intervention: FBR1 (HRT of 8h) without nitrate (Phase V)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: FBR2 (HRT of 12h) with ethanol and nitrate addition (Phase I)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: FBR2 (HRT of 12h)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: FBR1 (HRT of 8h) without ethanol (Phase IV)
Number of subjects: 2

Group type: COMPARATOR
Intervention: FBR1 (HRT of 8h) with ethanol (Phase II)
Number of subjects: 2
Study: 25263527

Group type: EXPERIMENTAL
Intervention: 3D bioresorbable PCL scaffold
Number of subjects: 13

Group type: COMPARATOR
Intervention: No space filler (control)
Number of subjects: 13
Study: 23429913

Group type: EXPERIMENTAL
Intervention: GSK961081 (400 μg once daily)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: GSK961081 (200 μg twice daily)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436

Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 436
Study: 21679318

Group type: EXPERIMENTAL
Intervention: Skiing intervention (12 weeks, average of 28.5 days of guided skiing)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (n=20; age: 67.3 ± 4.4 years)
Number of subjects: 27
Study: 18094013

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy
Number of subjects: 0
Study: 16877299

Group type: EXPERIMENTAL
Intervention: D-Ala1-peptide T-amide (DAPTA) at a dose of 2 mg three times per day (tid)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 12890601

Group type: COMPARATOR
Intervention: Mother-daughter sexual risk communication
Number of subjects: 219
Study: 10638883

Group type: EXPERIMENTAL
Intervention: Presence of the object (participants reached forward with the impaired arm to scoop coins)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Absence of the object (participants reached forward to the place where coins would be placed)
Number of subjects: 39
Study: 8623790

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 657
Study: 1356459

Group type: EXPERIMENTAL
Intervention: Fosfomycin 8 g and metronidazole 1 g before operation and fosfomycin 8 g eight hours afterwards
Number of subjects: 559

Group type: COMPARATOR
Intervention: Doxycycline 400 mg and metronidazole 1 g before operation, and placebo eight hours afterwards
Number of subjects: 559
Study: 3883878

Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31691886

Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 0
Study: 29193234

Group type: EXPERIMENTAL
Intervention: Ropivacaine-dexmedetomidine group (group RD, n = 19) received 15 mL of 0.5% ropivacaine with 100 μg (1 mL) dexmedetomidine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ropivacaine-dexmedetomidine group (group RD, n = 19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ropivacaine group (group R, n = 18)
Number of subjects: 37
Study: 28238618

Group type: EXPERIMENTAL
Intervention: Immediate re-feed post-simulation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Delayed re-feed (2-h post)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All players (post-simulation)
Number of subjects: 15
Study: 25326169

Group type: EXPERIMENTAL
Intervention: Eptifibatide (0.2 mg/kg intra-arterial bolus)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparin and/or aspirin (control group)
Number of subjects: 100
Study: 24273969

Group type: EXPERIMENTAL
Intervention: DFSE + controlled ovarian hyperstimulation (COH)
Number of subjects: 70

Group type: COMPARATOR
Intervention: DFSE placebo + controlled ovarian hyperstimulation (COH)
Number of subjects: 70
Study: 21142353

Group type: EXPERIMENTAL
Intervention: Experimental condition (video intervention)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control condition (neutral video)
Number of subjects: 138
Study: 18772807

Group type: EXPERIMENTAL
Intervention: Cataract surgery in late-stage AMD (n=12)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cataract surgery in early-stage AMD (n=30)
Number of subjects: 30
Study: 17157651

Group type: EXPERIMENTAL
Intervention: Symptom questionnaires
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: Simple questionnaire concerning the preceding 2 weeks
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: Baseline data including asthma questionnaires
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: Rescue medications and peak flow measurements
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids and unscheduled health care visits
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: Risk factors (smoking, ethnicity, lung function, asthma history)
Number of subjects: 2032
Study: 14567168

Group type: EXPERIMENTAL
Intervention: Agomelatine 5 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Agomelatine 100 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 28
Study: 11503260

Group type: EXPERIMENTAL
Intervention: Ceftibuten, 400 mg once daily
Number of subjects: 406

Group type: COMPARATOR
Intervention: Other antibiotics (b.i.d. dosing)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Other antibiotics (t.i.d. dosing)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Overall compliance for all groups
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Dosing frequency
Number of subjects: 406
Study: 9689270

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 4 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 8184352

Group type: EXPERIMENTAL
Intervention: Experimental treatment including specific manual treatment, such as manipulation and specific mobilization, muscle stretching, auto-traction, and cortisone injections
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional activating treatment
Number of subjects: 53
Study: 3812341

Group type: EXPERIMENTAL
Intervention: Freshly cooked potato
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cooked and cooled potato
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reheated potato
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cooled potato (large lumps vs finely sieved)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro studies with pancreatin
Number of subjects: 0
Study: 29458940

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with 5% lavender oil for 10 minutes before surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 80
Study: 28701798

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no CBT)
Number of subjects: 60
Study: 26152416

Group type: EXPERIMENTAL
Intervention: Emodepside/Praziquantel Spot-on (Profender®) - single application (3 mg/kg emodepside and 12 mg/kg praziquantel)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Emodepside/Praziquantel Spot-on (Profender®) - two applications (14 days apart)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 16
Study: 23826388

Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI)
Number of subjects: 0
Study: 21176949

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (375 mg/m² every 8 weeks)
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 1217
Study: 18279829

Group type: EXPERIMENTAL
Intervention: Oral estradiol 2.0 mg/day for 2 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral estradiol 4.0 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral estradiol 2.0 mg/day + medroxyprogesterone acetate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 microg
Number of subjects: 40
Study: 16921034

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily
Number of subjects: 731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study: 12456499

Group type: EXPERIMENTAL
Intervention: Estrogen therapy with factor XIIIA Leu34 allele
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Estrogen therapy with factor XIIIB Arg95 allele
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Homozygous for both common factor XIII alleles with Arg95 variant and Leu34 variant
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Current estrogen users with at least 2 copies of variant factor XIII alleles
Number of subjects: 955
Study: 10326073

Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 1309
Study: 8592524

Group type: EXPERIMENTAL
Intervention: Oral iron (100 mg per day) and subcutaneous erythropoietin (150 U per kilogram of body weight twice per week)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oral iron and placebo
Number of subjects: 34
Study: 1955630

Group type: EXPERIMENTAL
Intervention: Disodium chromoglycate
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Budesonide (4 weeks treatment)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Budesonide (one dose before exercise)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Histamine challenge
Number of subjects: 22
Study: 6275778

Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral antibiotics
Number of subjects: 0